1. The use of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one or its tautomer or its pharmaceutically acceptable salt for the treatment of adenocystic carcinoma. 2. A method for reducing solid tumors or preventing the progression of solid tumors in a subject with adenocystic carcinoma, comprising administering a therapeutically effective amount of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl ] -1H-quinolin-2-one or a pharmaceutically acceptable salt thereof in combination with docetaxel or a pharmaceutically acceptable salt thereof. 3. Use of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for for the preparation of a medicament for the treatment of solid tumors in a subject with adenocystic carcinoma. 4. Combination of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one or its tautomer or pharmaceutically acceptable salt and docetaxel for use in the treatment of adenocystic carcinoma. 5. A method for reducing solid tumors in a subject with adenocystic carcinoma, comprising administering a therapeutically effective amount of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinoline -2-one or a tautomer thereof or a pharmaceutically acceptable salt thereof in combination with docetaxel or a pharmaceutically acceptable salt thereof. 6. The use of the combination according to claim 4 for the manufacture of a medicament for the treatment or prevention of solid tumor growth in a patient with adenocystic carcinoma. 7. Use of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-o
展开▼
